# GILEAD SCIENCES, INC. (GILD) FY2025 Q1 P&L / Income Statement - Company: GILEAD SCIENCES, INC. (GILD) - Period: 2025-01-01 to 2025-03-31 - Filing: Q1 FY2025 10-Q, filed 2025-05-07, accession number 0000882095-25-000012 - Page: https://plicit.ai/financials/gild/fy2025-q1-income-statement - Chart image: https://plicit.ai/charts/gild-fy2025-q1-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,667,000,000 US dollars - **Cost of goods sold**: 1,540,000,000 US dollars - **Gross profit (calculated)**: 5,127,000,000 US dollars - **Operating expenses (calculated)**: 2,890,000,000 US dollars - **Operating income (loss)**: 2,237,000,000 US dollars - **Other income (expense), net (calculated)**: negative 588,000,000 US dollars - **Income (loss) before income taxes**: 1,649,000,000 US dollars - **Income tax expense (benefit)**: 334,000,000 US dollars - **Net income (loss)**: 1,315,000,000 US dollars - **Tecartus - UNITED STATES**: 40,000,000 US dollars - **Tecartus - Rest of World**: 8,000,000 US dollars - **Tecartus - Europe**: 31,000,000 US dollars - **Total Cell Therapy - UNITED STATES**: 200,000,000 US dollars - **Total Cell Therapy - Rest of World**: 84,000,000 US dollars - **Total Cell Therapy - Europe**: 180,000,000 US dollars - **Total HIV - UNITED STATES**: 3,664,000,000 US dollars - **Total HIV - Rest of World**: 370,000,000 US dollars - **Total HIV - Europe**: 553,000,000 US dollars - **Biktarvy - UNITED STATES**: 2,474,000,000 US dollars - **Biktarvy - Rest of World**: 301,000,000 US dollars - **Biktarvy - Europe**: 375,000,000 US dollars - **Descovy - UNITED STATES**: 538,000,000 US dollars - **Descovy - Rest of World**: 27,000,000 US dollars - **Descovy - Europe**: 21,000,000 US dollars - **Genvoya - UNITED STATES**: 305,000,000 US dollars - **Genvoya - Rest of World**: 19,000,000 US dollars - **Genvoya - Europe**: 40,000,000 US dollars - **Odefsey - UNITED STATES**: 215,000,000 US dollars - **Odefsey - Rest of World**: 10,000,000 US dollars - **Odefsey - Europe**: 57,000,000 US dollars - **Other HIV - UNITED STATES**: 50,000,000 US dollars - **Other HIV - Rest of World**: 10,000,000 US dollars - **Other HIV - Europe**: 31,000,000 US dollars - **Symtuza - Revenue share - UNITED STATES**: 82,000,000 US dollars - **Symtuza - Revenue share - Rest of World**: 3,000,000 US dollars - **Symtuza - Revenue share - Europe**: 29,000,000 US dollars - **Total Liver Disease - UNITED STATES**: 335,000,000 US dollars - **Total Liver Disease - Rest of World**: 256,000,000 US dollars - **Total Liver Disease - Europe**: 168,000,000 US dollars - **Other Liver Disease - UNITED STATES**: 68,000,000 US dollars - **Other Liver Disease - Rest of World**: 17,000,000 US dollars - **Other Liver Disease - Europe**: 76,000,000 US dollars - **Sofosbuvir/Velpatasvir - UNITED STATES**: 166,000,000 US dollars - **Sofosbuvir/Velpatasvir - Rest of World**: 99,000,000 US dollars - **Sofosbuvir/Velpatasvir - Europe**: 80,000,000 US dollars - **Vemlidy - UNITED STATES**: 100,000,000 US dollars - **Vemlidy - Rest of World**: 140,000,000 US dollars - **Vemlidy - Europe**: 12,000,000 US dollars - **Total Oncology - UNITED STATES**: 381,000,000 US dollars - **Total Oncology - Rest of World**: 121,000,000 US dollars - **Total Oncology - Europe**: 255,000,000 US dollars - **AmBisome - UNITED STATES**: 5,000,000 US dollars - **AmBisome - Rest of World**: 66,000,000 US dollars - **AmBisome - Europe**: 67,000,000 US dollars - **Other - UNITED STATES**: 47,000,000 US dollars - **Other - Rest of World**: 14,000,000 US dollars - **Other - Europe**: 9,000,000 US dollars - **Total Other - UNITED STATES**: 52,000,000 US dollars - **Total Other - Rest of World**: 81,000,000 US dollars - **Total Other - Europe**: 76,000,000 US dollars - **Yescarta - UNITED STATES**: 160,000,000 US dollars - **Yescarta - Rest of World**: 77,000,000 US dollars - **Yescarta - Europe**: 149,000,000 US dollars - **Royalty, contract and other revenues - UNITED STATES**: 37,000,000 US dollars - **Royalty, contract and other revenues - Rest of World**: 6,000,000 US dollars - **Royalty, contract and other revenues - Europe**: 11,000,000 US dollars - **Trodelvy - UNITED STATES**: 181,000,000 US dollars - **Trodelvy - Rest of World**: 37,000,000 US dollars - **Trodelvy - Europe**: 75,000,000 US dollars - **Veklury - UNITED STATES**: 199,000,000 US dollars - **Veklury - Rest of World**: 82,000,000 US dollars - **Veklury - Europe**: 22,000,000 US dollars - **Product sales - UNITED STATES**: 4,631,000,000 US dollars - **Product sales - Rest of World**: 909,000,000 US dollars - **Product sales - Europe**: 1,073,000,000 US dollars - **Selling, general and administrative expenses**: 1,258,000,000 US dollars - **Acquired in-process research and development expenses**: 253,000,000 US dollars - **Research and development expenses**: 1,379,000,000 US dollars - **In-process research and development impairments**: 0 US dollars - **Revenue before reconciliation (calculated)**: 20,057,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 13,390,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (16 categories) - Page: https://plicit.ai/financials/gild/fy2025-q1-income-statement/revenue-by-product-and-service-16-categories - Chart image: https://plicit.ai/charts/gild-fy2025-q1-revenue-by-product-and-service-16-categories-sankey.png Income statement for 2025-01-01 through 2025-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,667,000,000 US dollars - **Cost of goods sold**: 1,540,000,000 US dollars - **Gross profit (calculated)**: 5,127,000,000 US dollars - **Operating expenses (calculated)**: 2,890,000,000 US dollars - **Operating income (loss)**: 2,237,000,000 US dollars - **Other income (expense), net (calculated)**: negative 588,000,000 US dollars - **Income (loss) before income taxes**: 1,649,000,000 US dollars - **Income tax expense (benefit)**: 334,000,000 US dollars - **Net income (loss)**: 1,315,000,000 US dollars - **Tecartus**: 78,000,000 US dollars - **Yescarta**: 386,000,000 US dollars - **Biktarvy**: 3,150,000,000 US dollars - **Descovy**: 586,000,000 US dollars - **Genvoya**: 364,000,000 US dollars - **Odefsey**: 281,000,000 US dollars - **Symtuza - Revenue share**: 114,000,000 US dollars - **Other HIV**: 91,000,000 US dollars - **Sofosbuvir/Velpatasvir**: 346,000,000 US dollars - **Vemlidy**: 252,000,000 US dollars - **Other Liver Disease**: 161,000,000 US dollars - **Trodelvy**: 293,000,000 US dollars - **AmBisome**: 139,000,000 US dollars - **Other**: 70,000,000 US dollars - **Royalty, contract and other revenues**: 54,000,000 US dollars - **Veklury**: 302,000,000 US dollars - **Selling, general and administrative expenses**: 1,258,000,000 US dollars - **Acquired in-process research and development expenses**: 253,000,000 US dollars - **Research and development expenses**: 1,379,000,000 US dollars - **In-process research and development impairments**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/gild/fy2025-q1-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/gild-fy2025-q1-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2025-01-01 through 2025-03-31. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,667,000,000 US dollars - **Cost of goods sold**: 1,540,000,000 US dollars - **Gross profit (calculated)**: 5,127,000,000 US dollars - **Operating expenses (calculated)**: 2,890,000,000 US dollars - **Operating income (loss)**: 2,237,000,000 US dollars - **Other income (expense), net (calculated)**: negative 588,000,000 US dollars - **Income (loss) before income taxes**: 1,649,000,000 US dollars - **Income tax expense (benefit)**: 334,000,000 US dollars - **Net income (loss)**: 1,315,000,000 US dollars - **Product sales**: 6,613,000,000 US dollars - **Royalty, contract and other revenues**: 54,000,000 US dollars - **Selling, general and administrative expenses**: 1,258,000,000 US dollars - **Acquired in-process research and development expenses**: 253,000,000 US dollars - **Research and development expenses**: 1,379,000,000 US dollars - **In-process research and development impairments**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/gild/fy2025-q1-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/gild-fy2025-q1-revenue-by-geography-sankey.png Income statement for 2025-01-01 through 2025-03-31. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 6,667,000,000 US dollars - **Cost of goods sold**: 1,540,000,000 US dollars - **Gross profit (calculated)**: 5,127,000,000 US dollars - **Operating expenses (calculated)**: 2,890,000,000 US dollars - **Operating income (loss)**: 2,237,000,000 US dollars - **Other income (expense), net (calculated)**: negative 588,000,000 US dollars - **Income (loss) before income taxes**: 1,649,000,000 US dollars - **Income tax expense (benefit)**: 334,000,000 US dollars - **Net income (loss)**: 1,315,000,000 US dollars - **UNITED STATES**: 4,668,000,000 US dollars - **Europe**: 1,084,000,000 US dollars - **Rest of World**: 915,000,000 US dollars - **Selling, general and administrative expenses**: 1,258,000,000 US dollars - **Acquired in-process research and development expenses**: 253,000,000 US dollars - **Research and development expenses**: 1,379,000,000 US dollars - **In-process research and development impairments**: 0 US dollars ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.